Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH5650D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company's proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, the only once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of products that address CNS disorders such as multiple sclerosis, schizophrenia, depression and addiction. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc (ALKS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alkermes Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alkermes Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alkermes Plc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Civitas Therapeutics Raises USD55 Million in Series C Financing 11

Partnerships 13

Reset Therapeutics Enters into Co-Development Agreement with Alkermes 13

Licensing Agreements 14

Biogen Enters into Licensing Agreement with Alkermes 14

Alkermes Enters into Licensing Agreement with Domain Therapeutics 15

Asset Transactions 16

Recro Pharma Acquires Certain Assets from Alkermes 16

Alkermes Plc-Key Competitors 18

Alkermes Plc-Key Employees 19

Alkermes Plc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 23

Financial Announcements 23

Oct 23, 2018: Alkermes announces third quarter 2018 financial results 23

Apr 26, 2018: Alkermes Plc Reports First Quarter 2018 Financial Results 25

Feb 14, 2018: Alkermes Reports Q4 2017 Financial Results 27

Oct 26, 2017: Alkermes Reports Third Quarter 2017 Financial Results 29

Jul 27, 2017: Alkermes Reports Second Quarter 2017 Financial Results 31

Apr 27, 2017: Alkermes Reports First Quarter 2017 Financial Results 32

Feb 15, 2017: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017 33

Corporate Communications 35

Mar 01, 2018: Alkermes Names James Robinson as President and Chief Operating Officer 35

Feb 14, 2018: Alkermes Names Shane Cooke As Board Director 36

May 30, 2017: Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs 37

Government and Public Interest 38

Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS 38

Sep 05, 2018: ALKERMES inspiration grants program will award Up to USD 1 Million for the development or expansion of innovative programs 39

Nov 09, 2017: Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders 40

Nov 09, 2017: Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence 41

Sep 06, 2017: Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders 42

Clinical Trials 43

Jun 29, 2017: Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia 43

Jun 08, 2017: Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients 45

May 01, 2017: Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Alkermes Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alkermes Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alkermes Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Alkermes Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Civitas Therapeutics Raises USD55 Million in Series C Financing 11

Reset Therapeutics Enters into Co-Development Agreement with Alkermes 13

Biogen Enters into Licensing Agreement with Alkermes 14

Alkermes Enters into Licensing Agreement with Domain Therapeutics 15

Recro Pharma Acquires Certain Assets from Alkermes 16

Alkermes Plc, Key Competitors 18

Alkermes Plc, Key Employees 19

Alkermes Plc, Other Locations 21

Alkermes Plc, Subsidiaries 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alkermes Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com